Answers are grounded in this paper and cite their sources.
Alys Pharmaceuticals has launched with $100 million in seed funding from Medicxi, a life sciences investment firm. The start-up will target dermatological conditions including atopic dermatitis, vitiligo, alopecia areata, and chronic spontaneous urticaria. Alys is an amalgamation of assets from Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, KliRNA Biotech, Nira Biosciences, and Vimelea Therapeutics. The company says it has more than 12 active programs. It hopes to produce up to 10 clinical proof-of-concept readouts over the next 3 years.
No takes yet. Share an insight, caveat, or question.
Sarah Braner (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: